TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19

The Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that originated in Chinese city of Wuhan has caused around 906,092 deaths and 28,040,853 confirmed cases worldwide (https://covid19.who.int/, 11 September 2020). In a life-threatening situation, where there is no specific and licensed...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Mohammad Azam Ansari, Qazi Mohammad Sajid Jamal, Suriya Rehman, Ahmad Almatroudi, Mohammad A. Alzohairy, Mohammad N. Alomary, Takshashila Tripathi, Ali H. Alharbi, Syed Farooq Adil, Mujeeb Khan, M. Shaheer Malik
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier 2020-11-01
Serie:Arabian Journal of Chemistry
Soggetti:
SARS-CoV-2
TAT-peptide
3CLpro main protease
COVID-19
In silico
Molecular docking
Accesso online:http://www.sciencedirect.com/science/article/pii/S1878535220303713
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi